Nitrofurantoin Iasis (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that bind to bacterial DNA, ribosomal proteins and enzymes. This disrupts essential bacterial processes, leading to inhibition of growth or bacterial death, particularly in the urinary tract where the drug reaches high concentrations.

The specific dose and dosing schedule of Nitrofurantoin Iasis are determined by the prescribing clinician based on the patient’s condition, renal function and local treatment guidelines. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Nitrofurantoin should be used during pregnancy only when clearly needed and after evaluating the risk‑benefit ratio. It is generally avoided in the first trimester and near term. While limited data exist for breastfeeding, caution is advised and the infant should be monitored for possible adverse effects.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitrofurantoin offers high urinary concentrations and activity against common uropathogens, making it effective for uncomplicated infections. Compared with broader‑spectrum agents such as fluoroquinolones, it has a narrower spectrum, lower risk of promoting resistance, but may be unsuitable in patients with reduced renal function.

Store Nitrofurantoin Iasis at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain stability.

Nitrofurantoin Iasis is administered orally, typically with a full glass of water. It may be taken with food or after meals to reduce gastrointestinal irritation, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include pulmonary toxicity such as interstitial pneumonitis, hepatic injury, severe allergic reactions (including Stevens‑Johnson syndrome), and hemolytic anemia in patients with G6PD deficiency. Patients should seek immediate medical attention if they experience respiratory symptoms, jaundice, rash or unexplained fatigue.

Nitrofurantoin Iasis is contraindicated in patients with known hypersensitivity to nitrofurantoin or other nitrofuran derivatives, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with a history of G6PD deficiency due to the risk of hemolysis.